View:
---------------------------- OMB APPROVAL ---------------------------- OMB Number: 3235-0415 Expires: October 31, 1997 Estimated average burden hours per response . . 14.90 ---------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1 )* ----- Myriad Genetics, Inc. - ------------------------------------------------------------------------------- (Name of Issuer) Common Stock - ------------------------------------------------------------------------------- (Title of Class of Securities) 62855J104 -------------------- (CUSIP Number) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 6 pages - ----------------------- --------------------- CUSIP NO. 62855J104 13G PAGE 2 OF 6 PAGES - ----------------------- --------------------- - ------------------------------------------------------------------------------ NAME OF REPORTING PERSON 1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Mark H. Skolnick - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2 (a) [_] (b) [_] - ------------------------------------------------------------------------------ SEC USE ONLY 3 - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 4 U.S.A. - ------------------------------------------------------------------------------ SOLE VOTING POWER 5 NUMBER OF 199,016 SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 6 408,724 OWNED BY ----------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 7 REPORTING 199,016 PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 8 408,724 - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 607,740 - ------------------------------------------------------------------------------ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES 10 CERTAIN SHARES* [_] N/A - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 6.8% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 12 IN - ------------------------------------------------------------------------------ *SEE INSTRUCTIONS BEFORE FILLING OUT! Page 2 of 6 pages Item 1(a) Name of Issuer -------------- Myriad Genetics, Inc. Item 1(b) Address of Issuer's Principal Executive Offices ----------------------------------------------- 320 Wakara Way Salt Lake City, UT 84108 Item 2(a) Name of Person Filing --------------------- Mark H. Skolnick Item 2(b) Address of Principal Business Office or, if none, Residence ----------------------------------------------------------- 390 Wakara Way Salt Lake City, UT 84108 Item 2(c) State of Organization/Citizenship --------------------------------- U.S.A. Item 2(d) Title of Class of Securities ---------------------------- Common Stock Item 2(e) CUSIP Number ------------ 62855J104 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d- ------------------------------------------------------------- 2(b), check whether the person filing is a ------------------------------------------ (a) [ ] Broker or Dealer registered under Section 15 of the Act (b) [ ] Bank as defined in Section 3(a)(6) of the Act (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (d) [ ] Investment Company registered under Section 8 of the Investment Company Act Page 3 of 6 pages (e) [ ] Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 (f) [ ] Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see (S)240.13d-1(b) (1)(ii)(F) (g) [ ] Parent Holding Company, in accordance with (S)40.13d-1(b) (1)(ii)(G) (h) [ ] Group, in accordance with (S)240.13d-1(b)(1)(ii)(H) Item 4. Ownership --------- (a) Amount Beneficially Owned: 607,740 (b) Percent of Class: 6.8% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 199,016 (ii) shared power to vote or to direct the vote: 408,724 (iii) sole power to dispose or to direct the disposition of: 199,016 (iv) shared power to dispose or to direct the disposition of: 408,724 Item 5. Ownership of Five Percent or Less of a Class -------------------------------------------- N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person --------------------------------------------------------------- N/A Item 7. Identification and Classification of the Subsidiary Which Acquired ------------------------------------------------------------------ the Security Being Reported on By the Parent Holding Company ------------------------------------------------------------ N/A Item 8. Identification and Classification of Members of the Group --------------------------------------------------------- N/A Page 4 of 6 pages Item 9. Notice of Dissolution of Group ------------------------------ N/A Item 10. Certification ------------- By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. Page 5 of 6 pages Signature --------- After reasonably inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 14, 1997 BY:/s/ Mark H. Skolnick ----------------------------------------- MARK H. SKOLNICK/EXECUTIVE VICE PRESIDENT RESEARCH This filing is made voluntarily and should not be construed as an admission that Mark H. Skolnick is subject to reporting requirements under Section 13 of the Securities Exchange Act of 1934.